Vir Biotechnology
209 hedge funds and large institutions have $901M invested in Vir Biotechnology in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 27 closing their positions.
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
13% more call options, than puts
Call options by funds: $3.04M | Put options by funds: $2.7M
1% more funds holding
Funds holding: 206 → 209 (+3)
4% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 68
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $909M → $901M (-$7.72M)
1.31% less ownership
Funds ownership: 67.13% → 65.83% (-1.3%)
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$10M |
| 2 |
Citigroup
New York
|
+$9.36M |
| 3 |
Barclays
London,
United Kingdom
|
+$5.8M |
| 4 |
O
OrbiMed
New York
|
+$5.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.77M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$27.2M |
| 2 |
Morgan Stanley
New York
|
-$19.5M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$3.29M |
| 4 |
TC
TwinBeech Capital
Purchase,
New York
|
-$3.22M |
| 5 |
BlackRock
New York
|
-$3.07M |
VIR Hedge Fund Activity: Q1 2024 in Review
209 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2024, worth a combined $901M — down 0.85% from $909M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new VIR positions and 27 closed out — a net gain of 4 holders — while 71 added to existing stakes and 68 trimmed.
The largest buyer was Bank of America, adding an estimated $10M. The largest seller was AllianceBernstein, cutting an estimated $27.2M.
- 209 institutional investors held Vir Biotechnology (VIR) as of Q1 2024, up from 206 in Q4 2023.
- Funds reported $901M of Vir Biotechnology stock for Q1 2024, down 0.85% quarter-over-quarter.
- 31 funds opened new Vir Biotechnology positions in Q1 2024 and 27 closed out, a net change of +4 holders.
- The largest Vir Biotechnology buyer in Q1 2024 was Bank of America, an estimated $10M added.
- The largest Vir Biotechnology seller in Q1 2024 was AllianceBernstein, an estimated $27.2M sold.
Based on aggregated 13F filings for Q1 2024.